Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis.
about
Pathogenesis, management and prevention of atypical femoral fracturesDo bisphosphonates cause femoral insufficiency fractures?Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspectsSynchrotron Imaging Assessment of Bone QualityNovel advances in the treatment of osteoporosis.The effect of antiresorptives on bone quality.Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis.One year of alendronate treatment lowers microstructural stresses associated with trabecular microdamage initiation.Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone ClubPotential pathophysiological mechanisms in osteonecrosis of the jaw.Collagen mutation causes changes of the microdamage morphology in bone of an OI mouse modelIs surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy?Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis.Bisphosphonates and atypical fractures of femur.Diseases affecting bone quality: beyond osteoporosis.Bone microdamage, remodeling and bone fragility: how much damage is too much damage?Age-related differences in the morphology of microdamage propagation in trabecular bone.Mechanical property and tissue mineral density differences among severely suppressed bone turnover (SSBT) patients, osteoporotic patients, and normal subjectsEffects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational StudyProtocol for a randomized controlled trial to compare bone-loading exercises with risedronate for preventing bone loss in osteopenic postmenopausal womenResearch perspectives: The 2013 AAOS/ORS research symposium on Bone Quality and Fracture Prevention.Density and architecture have greater effects on the toughness of trabecular bone than damage.Long-term effects of bisphosphonate therapy: perforations, microcracks and mechanical properties.Bisphosphonates and atypical subtrochanteric fractures of the femur.Use of bisphosphonates in the management of postmenopausal osteoporosis.Microarchitectural adaptations in aging and osteoarthrotic subchondral bone issues.Current options for the management of postmenopausal osteoporosis.Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw.Review: epidemiology and pathophysiology of atypical femur fractures.Pharmacology of Bisphosphonates in Patients with Chronic Kidney Disease.Odanacatib for the treatment of osteoporosis.Treatment of Osteoporosis with Antiresoptive agent, Alendronate - warrants careful follow-up.Bone micromechanical properties are compromised during long-term alendronate therapy independently of mineralization.The effect of long-term bisphosphonate therapy on trabecular bone strength and microcrack density.Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in perimenopausal women.Three years of alendronate treatment does not continue to decrease microstructural stresses and strains associated with trabecular microdamage initiation beyond those at 1 year.Methodological approach for the detection of both microdamage and fluorochrome labels in ewe bone and human trabecular bone.Cortical bone quality affectations and their strength impact analysis using holographic interferometry
P2860
Q26824555-33EFF4B3-B165-4620-96B9-54104C708FA9Q27021396-6FFB98D1-68F9-4109-936B-994373DD68F4Q27025945-D63167EE-94E4-422A-9024-C46A4A2BCD65Q28075733-48FA5F7E-0335-46FD-96E2-E12A416AACA5Q30248319-2D4518DC-7C0F-44AA-A0F7-33912944EA88Q33896122-B6CC16A7-C500-4B42-8014-083656672C3DQ34018048-1949B5A5-5E33-4480-A829-76BADC7F00B4Q34053936-8D07559A-A3A3-470E-A2BB-308C3951629EQ34099162-C43FEB90-612F-4C96-9D2B-981CE9C6F384Q34162359-CD99BB56-771F-4703-9451-8E721B1AD08FQ34268022-A6946D66-FD09-4BC9-B22B-B9B9915488F3Q34283772-0F18489E-1B90-4ADD-BF92-2589BEE9E407Q34395462-00F8EE1D-4104-46D4-B603-184F365B8C85Q34986933-0BFDB374-55EA-4B39-B663-CF67955847A0Q35078847-60EC422D-9F9A-44B3-A316-E024159881ADQ35211086-3453E1C2-0FC1-4433-8AF9-AE3EE2C35ACBQ35291434-D322C8CC-3E4D-42F5-9FE1-7028C4C3EA27Q35566438-5209D450-3AF0-4A17-BA96-0AA02875EC44Q35598005-882D2A8C-CD12-4410-A07D-C8382744EAB9Q36117213-49B1FC9E-FD65-4F5D-8DF9-C86395E0DAADQ36473294-545A3DA0-CACE-4326-B43E-C1EC970DC8F3Q37352318-D9D3B838-7BC8-4972-94B4-0230FF6BD506Q37682081-E51B00ED-F570-4F78-B944-FF9D6C10505AQ37733851-ADC55E69-6A57-43BF-8AF7-65671AC545BDQ37800181-EDB841F8-CA08-4084-BDFC-610991374F15Q37812618-E8D0616E-AC34-4519-B269-5517CD4CF69FQ37931985-30D50661-9A41-4424-97ED-A7299B22B896Q37945476-5B3DA090-1B14-403C-8938-BC3C25F7BA5EQ38187901-A9681D30-673C-48C9-8F7D-7067A5C9A868Q38458773-216DFE0D-5BAD-4E32-B602-6F6BEF5884ECQ38543387-38BC8706-C1FD-4A8F-BC51-5B2A8BA7E49CQ39703171-6C311C9E-5F5B-4D9C-9704-B517DBADB141Q46292054-3318ABA2-8441-4605-8DF3-18525F435719Q47119987-1A990D13-E034-4689-A217-B6F1E7248AEBQ48265576-BB8CB344-86B2-4BEA-B8CB-35FEA30FC7C4Q50504521-E4EC212C-5202-4FF2-8EDD-8A3EADECD40CQ50516899-708BBCDF-5BB8-4184-9C3A-74561805FDD5Q57493454-A1827860-BB4D-4299-A531-AE5874DC9E54
P2860
Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Low bone mineral density is as ...... ausal women with osteoporosis.
@ast
Low bone mineral density is as ...... ausal women with osteoporosis.
@en
Low bone mineral density is as ...... ausal women with osteoporosis.
@nl
type
label
Low bone mineral density is as ...... ausal women with osteoporosis.
@ast
Low bone mineral density is as ...... ausal women with osteoporosis.
@en
Low bone mineral density is as ...... ausal women with osteoporosis.
@nl
prefLabel
Low bone mineral density is as ...... ausal women with osteoporosis.
@ast
Low bone mineral density is as ...... ausal women with osteoporosis.
@en
Low bone mineral density is as ...... ausal women with osteoporosis.
@nl
P2093
P1433
P1476
Low bone mineral density is as ...... ausal women with osteoporosis.
@en
P2093
Adrien Sipos
Astrid Fahrleitner-Pammer
Dana Michalska
David B Burr
David Michalsky
Harald Dobnig
Helmut Petto
Jan J Stepan
Jiliang Li
P304
P356
10.1016/J.BONE.2007.04.198
P577
2007-05-18T00:00:00Z